Ari Bhatt

Ari Bhatt studies how epigenomic driver mutations reshape the cancer epigenome and drive malignant transformation, with particular focus on leukemia. His research characterized DNMT3A mutations as early epigenomic events that predispose hematopoietic stem cells to leukemia development through clonal hematopoiesis. He has also studied how IDH1/2 mutations cause widespread DNA hypermethylation by producing the oncometabolite 2-hydroxyglutarate. His work identified epigenomic vulnerabilities created by these driver mutations that can be therapeutically exploited.